Jefferson Health

Physician Profile

Steven Cohen, MD

Chief, Medical Oncology and Hematology Division, Abington Hospital
Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Jefferson

Medical Oncology
Medical Oncology - Colorectal Cancer
Medical Oncology - Esophageal Cancer
Medical Oncology - Gastrointestinal (GI) Cancer
Medical Oncology - Liver Cancer
Medical Oncology - Pancreatic Cancer
Medical Oncology - Stomach Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

1200 Old York Road
1 Widener - AMH
Abington PA 19001
Phone: (215) 481-2400
Fax: (215) 481-7438
925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340

Board Certifications

  • Medical Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Abington Hospital

Awards and Honors

NCI Clinical Investigator Team Leadership Award

ASCO Leadership Development Program Graduate


  • SUNY at Stony Brook School of Medicine, Medical School


  • Temple University Hospital


  • Temple University Hospital


  • Fox Chase Cancer Center

Recent Publications

Neoadjuvant therapy for rectal cancer affects lymph node yield and status without clear implications on outcome: The case for eliminating a metric and using preoperative staging to guide therapy

Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer

Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer

Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients with Metastatic Pancreatic Adenocarcinoma

Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: A Fox Chase Cancer Center Pilot Study

CALGB 80403 (Alliance)/E1206: A randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal Junction Cancers

Dosimetric predictors of hematologic toxicity in patients undergoing concurrent gemcitabine-based chemoradiation for localized pancreatic cancer

Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264

A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: An Academic Oncology GI Cancer Consortium study

Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection

Young Age Increases Risk for Lymph Node Positivity in Early-Stage Rectal Cancer

Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer

A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer [Ann Oncol (2015), 26, 1923-1929]

Association of treatment factors with surgical outcomes in tri-modality therapy for esophageal cancer

<sup>90</sup>Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation

Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer

Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer